Author name: Leonardo Arias

The collaboration will pair biometric data from the Oura ring with data from glucose sensors and insulin pumps.

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, with the exception of Eli Lilly’s orforglipron, the vouchers are for drugs that are already on the market.

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.

Dr. Amy Flaster, Cigna Healthcare’s chief medical officer since last year, is stepping up as CMO of the whole enterprise. At the same time, Cigna’s chief health officer and a business improvement executive are hitting the road.

More than 450 telehealth and provider organizations are pushing lawmakers to avoid another temporary extension of telemedicine flexibilities amid a historic government shutdown.

However, the sequencing company said it remains on China’s unreliable entity list, and it is working toward a long-term resolution of the issue.

The company expects to fully offset the negative effects of tariffs in the medium term.

More than 70% reported moderate to severe financial effects from an incident in the past two years, while nearly 60% cited clinical impacts, according to the report by Ernst & Young and Klas Research.

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting campaign is helping to stem the downward trend.